Efficacy of Ceftazidime-avibactam in treating Gram-negative infections: a systematic review and meta-analysis
Authors:
- Nahal KhoshdelNKNahal Khoshdel
- Melina NoursalehigarakaniMNMelina Noursalehigarakani
- Zahra Sadat SeghatoleslamiZSZahra Sadat Seghatoleslami
- Fahimeh HadavandFHFahimeh Hadavand
- Elaheh EghbalEEElaheh Eghbal
- Mohammad Javad NasiriMNMohammad Javad Nasiri
- Elena SimulaESElena Simula
- Parnian AhmedPAParnian Ahmed
- Leonardo Antonio SechiLeonardo Antonio Sechi
Open Access
- 22 January 2025
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (4) , 767-778
Abstract
Introduction: Ceftazidime-avibactam (CAZ-AVI) has emerged as a promising treatment option for Gram-negative infections, particularly those caused by CAZ-Non-Susceptible (NS) pathogens. This systematic review and meta-analysis aim to assess the efficacy and safety of CAZ-AVI in these challenging infections. Methods: We systematically queried EMBASE, Cochrane CENTRAL, and PubMed/Medline for studies published until September 15, 2024. Randomized Controlled Trials (RCTs) evaluating CAZ-AVI against Gram-negative infections were included. A meta-analysis was performed to calculate pooled odds ratios (OR) for both clinical and microbiological success. Results: A total of 146 studies were identified through database searches, leading to the inclusion of 17 studies. Among the efficacy studies for Gram-negative pathogens, there was no significant difference in clinical success rates for CAZ-AVI compared to comparators (pooled OR: 0.90, p = 0.22), and a non-significant increase in microbiological success was observed (pooled OR: 1.20, p = 0.41). In contrast, for CAZ-NS pathogens, six studies reported no significant difference in clinical cure rates (pooled OR: 0.77, p = 0.24), while four studies indicated a non-significant increase in microbiological cure rates (pooled OR: 1.83, p < 0.02). Conclusions: This study suggests that CAZ-AVI is a viable option for treating Gram-negative infections, including CAZ-NS pathogens. While it has shown promising activity against these resistant pathogens, its clinical and microbiological success rates are comparable to other antibiotics in the overall analysis. However, CAZ-AVI may offer an advantage in managing resistant infections. These findings underscore the need to consider CAZ-AVI in treatment guidelines and emphasize the importance of antibiotic stewardship programs to optimize its use and prevent resistance. Ongoing monitoring of resistance patterns and patient outcomes is essential to ensure its long-term efficacy.Keywords
Funding Information
- Università degli Studi di Sassari
This publication has 36 references indexed in Scilit:
- Association Between Antimicrobial Stewardship Programs and Antibiotic Use GloballyJAMA Network Open, 2023
- Estimating the Economic and Clinical Value of Introducing Ceftazidime/Avibactam into Antimicrobial Practice in Japan: A Dynamic Modelling StudyPharmacoEconomics - Open, 2022
- Update of clinical application in ceftazidime–avibactam for multidrug-resistant Gram-negative bacteria infectionsInfection, 2022
- Safety Profile of Ceftazidime–Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial ProgrammeDrug Safety, 2020
- Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in ItalyClinical Therapeutics, 2020
- Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal ImpairmentThe Journal of Clinical Pharmacology, 2016
- A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese SubjectsClinical Drug Investigation, 2015
- Randomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjectsPharmacology Research & Perspectives, 2015
- Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled StudiesClinical Drug Investigation, 2015
- Randomized, placebo‐controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime–avibactam or ceftaroline fosamil–avibactamThe Journal of Clinical Pharmacology, 2013